bioMérieux Stock Price, News & Analysis (OTCMKTS:BMXMF) $107.31 0.00 (0.00%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$107.31▼$107.3150-Day Range$91.62▼$108.9552-Week Range$90.23▼$110.00Volume300 shsAverage Volume149 shsMarket Capitalization$12.70 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest About bioMérieux Stock (OTCMKTS:BMXMF)bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.Read More BMXMF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMXMF Stock News HeadlinesOctober 19, 2023 | marketwatch.comOxford Nanopore Shares Rise on Backed Guidance, GBP70 Mln Investment by bioMerieuxOctober 26, 2022 | msn.combioMerieux : les résultats 2022 devraient se situer dans la borne haute des intervalles publiés en aoûtDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.April 13, 2022 | msn.combioMerieux : du mieuxApril 12, 2022 | msn.combioMerieux recule après les annoncesMarch 3, 2022 | seekingalpha.combioMérieux S.A. GAAP EPS of €5.06, revenue of €3.37MJanuary 7, 2022 | finance.yahoo.comFrench multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistanceOctober 21, 2021 | finance.yahoo.comBaxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney InjuryDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 5, 2021 | finance.yahoo.combioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021March 23, 2021 | finanznachrichten.debioMérieux - 2020 Financial ResultsMarch 3, 2021 | news.yahoo.comGoogle insiders reveal why the company's ambitious plan to create major video games fell apartSeptember 29, 2020 | finanznachrichten.debioMérieux - First-Half 2020 ResultsSeptember 27, 2020 | finance.yahoo.comFrench labs show how global supply bottlenecks thwart effort to ramp up testingSeptember 10, 2020 | finance.yahoo.comWhat Makes BIOMERIEUX (BMXMF) a New Buy StockSeptember 5, 2020 | marketwatch.comCOVID-19 Diagnostics Market Clinical Reviews by Expert and Healthcare Analysis 2020September 3, 2020 | seekingalpha.combioMérieux SA (BMXMF) CEO Alexandre Mérieux on Q2 2020 Results - Earnings Call TranscriptSeptember 2, 2020 | seekingalpha.combioMérieux S.A. 2020 Q2 - Results - Earnings Call PresentationJuly 27, 2020 | finance.yahoo.comWhat Makes BIOMERIEUX (BMXMF) a New Strong Buy StockJuly 15, 2020 | finance.yahoo.comBIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE markedJune 30, 2020 | finance.yahoo.combioMérieux: Description of the New Share Buyback Program Pursuant to Article 241-1 to Article 241-6 of the AMF General RegulationsJune 29, 2020 | finance.yahoo.combioMérieux Issues a €200 Million Euro PP BondMay 30, 2020 | finance.yahoo.comDrugs standards group nixes plan to kick pharma's crab blood habitMay 27, 2020 | finance.yahoo.comAll You Need to Know About BIOMERIEUX (BMXMF) Rating Upgrade to BuyMay 23, 2020 | finance.yahoo.combioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020May 21, 2020 | finance.yahoo.comCE Marking of bioMérieux Serology Tests for SARS-CoV-2 on VIDAS®May 19, 2020 | finance.yahoo.comInformation Concerning 2019 Dividend and the bioMérieux General Shareholders’ MeetingSee More Headlines Receive BMXMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BMXMF CUSIPN/A CIKN/A Webwww.biomerieux.com Phone33-04-78-87-20-00Fax33-04-78-87-20-90Employees13,800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.09 Current Ratio2.20 Quick Ratio1.34 Sales & Book Value Annual Sales$3.78 billion Price / Sales3.36 Cash Flow$5.81 per share Price / Cash Flow18.48 Book Value$32.43 per share Price / Book3.31Miscellaneous Outstanding Shares118,360,000Free FloatN/AMarket Cap$12.70 billion OptionableNot Optionable Beta0.88 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Alexandre Merieux (Age 49)Executive Chairman Comp: $1.52MMr. Pierre Boulud (Age 52)Chief Executive Officer Comp: $1.15MMr. Frederic Beseme (Age 67)Head of CSR Comp: $24.19kMr. Guillaume Bouhours (Age 47)Executive VP of Purchasing and Information Systems & CFO Sylvain MorgeauInvestor RelationsMs. Audrey Dauvet (Age 49)Executive Vice President of Legal Affairs & Integrity Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSRMr. François LacosteExecutive Vice President of R&DMr. Mark MillerExecutive VP & Chief Medical OfficerMr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply ChainMore ExecutivesKey CompetitorsSysmexOTCMKTS:SSMXYEurofins ScientificOTCMKTS:ERFSFRecordati Industria Chimica e FarmaceuticaOTCMKTS:RCDTFSino BiopharmaceuticalOTCMKTS:SBMFFEisaiOTCMKTS:ESALYView All Competitors BMXMF Stock Analysis - Frequently Asked Questions Should I buy or sell bioMérieux stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMXMF shares. View BMXMF analyst ratings or view top-rated stocks. How have BMXMF shares performed in 2023? bioMérieux's stock was trading at $106.00 at the start of the year. Since then, BMXMF stock has increased by 1.2% and is now trading at $107.31. View the best growth stocks for 2023 here. How do I buy shares of bioMérieux? Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:BMXMF) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioMérieux S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.